Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
British Journal of Haematology, 05/11/2012Forni GL et al.
The findings suggest that in this largest randomized trial in thalassaemia–induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing bone mineral density (BMD). The associated reduction in back pain and improved quality of life will encourage adherence to therapy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.